Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma
The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biom...
Main Authors: | Karen E. Mulder, Jennifer L. Spratlin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2011-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/12/9/5895/ |
Similar Items
-
Emerging Roles of Nucleoside Transporters
by: Marçal Pastor-Anglada, et al.
Published: (2018-06-01) -
Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters
by: Ying-Si Wu, et al.
Published: (2021-04-01) -
Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions
by: Jennifer L. Spratlin, et al.
Published: (2010-12-01) -
hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
by: Jerome Raffenne, et al.
Published: (2019-11-01) -
Renal proximal tubular handling of nucleosides by human nucleoside transporter proteins
by: Elwi, Adam
Published: (2009)